(Q36150601)

English

Emerging anti-HIV drugs

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

Emerging anti-HIV drugs (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

object named as

Erik De Clercq

1

0 references

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Expert Opinion on Emerging Drugs

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

241-273

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Antiviral drugs in current clinical use.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Strategies in the design of antiviral drugs

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Antivirals and antiviral strategies

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Resistance to enfuvirtide, the first HIV fusion inhibitor

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissocia

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

The bicyclam AMD3100 story

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

New class of HIV integrase inhibitors that block viral replication in cell culture

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.241

21 January 2018

Identifiers

10.1517/14728214.10.2.241

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36150601&oldid=2005123198"